These lesions can start as insignificant patches and may remain undiagnosed for up to a decade. Hypopigmentation (when the skin is lighter than normal) of lesions are less common but can be found in children, adolescents and/or dark-skinned individuals.The advanced stage of mycosis fungoides is characterized by generalized erythroderma (red rash covering most of the body) with severe pruritus (itching) and scaling. Itching (Pruritus) is the most commonly reported symptom of people experiencing mycosis fungoides with up to 88% of people reporting varying intensities of pruritus that typically worsens as the disease progresses. Those that experience intense pruritus commonly indicate that it negatively affects their quality of life emotionally, functionally and physically.Mycosis fungoides (MF) and Sézary syndrome (SS) are related conditions with the same type of cancer t-lymphocytes that initially grow in different body compartments. SS cells are mainly found in the blood, whereas MF typically involves the skin. In advanced stages of MF, the cancer cells move from the skin into the blood stream and other organs, and is referred to as  "leukemic mycosis fungoides", :Sézary syndrome preceded by mycosis fungoides", or "secondary mycosis fungoides". Cause
Mycosis fungoides is caused by abnormal white blood cells (T-lymphocytes). These abnormal cells have a preference for localizing and proliferating uncontrolled in the outer layer of the skin (epidermis). The abnormal cells may later involve other organs such as the lymph nodes.
Repaglinide is an antidiabetic drug in the class of medications known as meglitinides, and was invented in 1983. Repaglinide is an oral medication used in addition to diet and exercise for blood sugar control in type 2 diabetes mellitus. The mechanism of action of repaglinide involves promoting insulin release from β-islet cells of the pancreas; like other antidiabetic drugs, a main side effect concern is hypoglycemia. It is sold by Novo Nordisk under the name of Prandin in the United States, GlucoNorm in Canada, Surepost in Japan, Repaglinide in Egypt by EIPICO, and NovoNorm elsewhere. In Japan it is produced by Dainippon Sumitomo Pharma. Medical uses
Repaglinide is an oral medication used in addition to diet and exercise for blood sugar control in type 2 diabetes mellitus. Contraindications
Repaglinide is contraindicated in people with:

Diabetic ketoacidosis, with or without coma
Type 1 diabetes
Co-administration with gemfibrozil
Known hypersensitivity to drug or inactive ingredients

Adverse events
Common adverse events include:Metabolic 

Hypoglycemia (31%)Respiratory

Upper respiratory infection (16%)
Sinusitis (6%)
Rhinitis (3%)Gastrointestinal

Nausea (5%)
Diarrhea (5%)
Constipation (3%)
Vomiting (3%)Musculoskeletal

Arthralgia (6%)
Back Pain (5%)Other

Headache (11%)
Paresthesia (3%)Serious adverse events include:
Cardiac ischemia (2%)
Angina (1.8%)
Deaths due to cardiovascular events (0.5%)

Special populations
Pregnancy category C: safety in pregnant women has not been established. Data is limited, and there is only one case report that notes no complications with the use of repaglinide during pregnancy.Caution should be taken in people with liver disease and decreased kidney function when using this medication. Drug interactions
Repaglinide is a major substrate of CYP3A4 and should not be administered concomitantly with gemfibrozil, clarithromycin or azole antifungals such as itraconazole or ketoconazole.